Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2011-08-30
2011-08-30
Kim, Yunsoo (Department: 1644)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C530S387500, C530S388250
Reexamination Certificate
active
08008024
ABSTRACT:
The invention involves assays, diagnostics, kits, and assay components for determining levels of K41-glycated CD59 in subjects. Treatments for subjects based upon levels of K41-glycated CD59 also are provided.
REFERENCES:
patent: 4281061 (1981-07-01), Zuk et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5225539 (1993-07-01), Winter
patent: 5470759 (1995-11-01), Sugiyama et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5789208 (1998-08-01), Sharon
patent: 5853703 (1998-12-01), Cerami et al.
patent: 5859205 (1999-01-01), Adair et al.
patent: 6835545 (2004-12-01), Halperin
patent: 7049082 (2006-05-01), Halperin
patent: 7439330 (2008-10-01), Halperin
patent: 2004/0219606 (2004-11-01), Halperin
patent: 2005/0032128 (2005-02-01), Halperin
patent: 2006/0257936 (2006-11-01), Halperin
patent: 2010/0009378 (2010-01-01), Halperin
patent: 0394035 (1990-10-01), None
patent: 1789449 (2007-05-01), None
patent: WO-98/19711 (1998-05-01), None
patent: WO-2004/106941 (2004-12-01), None
patent: WO-2006/009533 (2006-01-01), None
patent: WO-2006/086098 (2006-08-01), None
Acosta et al., Complement and complement regulatory proteins as potential molecular targets for vascular diseases. Current Pharmaceutical Design, 2004;10:1-9.
Acosta, et al., Molecular basis for a link between complement and the vascular complications of diabetes. Proc Natl Acad Sci 97: 5450-5455, 2000.
Benzaquen, et al., Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells. J. Exp. Med. 179: 985-992, 1994.
Bodian et al., Mutational analysis of the active site and antibody epitopes of the complement-inhibitory glycoprotein, CD59. J Exp Med. Feb. 3, 1997;185(3):507-16.
Davies, et al., CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J. Exp. Med,. 170 (3): 637-654, 1989.
Fletcher, et al., Structure of a soluble, glycosylated form of the human complement regulatory protein CD59. Structure, 2: 185-199, 1994.
Halperin, et al., Terminal complement complex C5b-9 stimulates mitogenesis in 3T3 cells. J. Clin. Invest., 91: 1974-1978, 1993.
Halperin, et al., Properties of the Na+-K+ pump in human red cells with increased number of pump sites. J. Clin. Invest., 80: 128-137, 1987.
Halperin, et al, Transient changes in erythrocyte membrane permeability are induced by sublytic amounts of the complement membrane attack complex (C5b-9). Blood 81: 200-205, 1993.
Harlow et al., Antibodies: A Laboratory Manual. 1998;321-323.
Hughes, et al., Isolation and characterization of a membrane protein from rat erythrocytes which inhibits lysis by the membrane attack complex of rat complement. Biochem. J., 284: 169-176, 1992.
Lapolla et al., the role of mass spectrometry in the study of non-enzymatic protein glycation in diabetes. Mass Spectrom Rev. Sep.-Oct 2000;19(5):279-304. Review.
Myint, et al., Immunological detection of glycated proteins in normal and streptozotocin-induced diabetic rats using anti hexitol-lysine IgG. Biochem. Biophys. Acta 1272: 73-79, 1995.
Philbrick, et al., The CD59 antigen is a structural homologue of murine Ly-6 antigens but lacks interferon inducibility. Eur. J. Immunol., 20: 87-92, 1990.
Qin, X. et al., A Role of Glycated Human Cd59 and the Complement System in the Pathogenesis of Chronic Vascular Complications of Diabetes. International Immunopharmacology, 2: 1382-1383, 2002.
Qin X. et al., Genomic Structure, Functional Comparison, and Tissue Distribution of Mouse Cd59a and Cd59b. Mammalian Genome, 12: 582-589, 2001.
Rosoklija, et al., Local activation of the complement system in endoneurial microvessels of diabetic neuropathy. Acta Neuro, 99: 55-62, 2000.
Suzuki et al., Immunofluorescence staining of renal biopsy samples in patients with diabetic nephropathy in non-insulin-dependent diabetes mellitus using monoclonal antibody to reduced glycated lysine. J Diabetes Complications. Nov.-Dec. 1996;10(6):314-9.
Takata et al., Glycated Cu,Zn-superoxide dismutase in rat lenses: evidence for the presence of fragmentation in vivo. Biochem Biophys Res Commun. Feb. 6, 1996;219(1):243-8.
Van Den Berg, et al., The sheep analogue of human CD59: purification and characterization of its complement inhibitory activity. Immunology 78: 349-357, 1993.
Walton et al., Synthesis of N-(1-deoxyhexitol-1-yl)amino acids, reference compounds for the nonenzymic glycosylation of proteins. Carbohydr Res. May 15, 1984;128(1):37-49.
Zhang, J. et al., Early Complement Activation and Decreased Levels of Glycosylphosphatidylinositol-Anchored Complement Inhibitors in Human and Experimental Diabetic Retinopathy. Diabetes, 51: 3499-3504, 2002.
Zhao, et al., Amplified gene expression in CD59-transfected Chinese hamster ovary cells confers protection against the membrane attack complex of human complement. J. Biol. Chem. 266: 13418-13422, 1991.
International Search Report mailed Aug. 27, 2008 in connection with application No. PCT/US2008/005831.
International Preliminary Report on Patentability mailed Dec. 20, 2006 in connection with application No. PCT/US2004/019392.
International Search Report mailed Oct. 30, 2006 in connection with application No. PCT/US2006/000310.
International Preliminary Report on Patentability mailed Jul. 19, 2007 in connection with application No. PCT/US2006/000310.
International Search Report mailed Jun. 6, 2005 in connection with application No. PCT/US2004/019392.
International Preliminary Report on Patentability mailed Nov. 19, 2009 in connection with application No. PCT/US2008/005831.
Office Action mailed Oct. 21, 2002 for U.S. Appl. No. 09/835,752.
Reply to Office Action mailed Mar. 19, 2003 for U.S. Appl. No. 09/835,752.
Office Action mailed Jun. 13, 2003 for U.S. Appl. No. 09/835,752.
Reply to Office Action mailed Jul. 11, 2003 for U.S. Appl. No. 09/835,752.
Office Action mailed Oct. 3, 2003 for U.S. Appl. No. 09/835,752.
Reply to Office Action mailed Oct. 20, 2003 for U.S. Appl. No. 09/835,752.
Office Action mailed Mar. 24, 2005 for U.S. Appl. No. 10/833,581.
Reply to Office Action mailed Sep. 26, 2005 for U.S. Appl. No. 10/833,581.
Office Action mailed Oct. 5, 2006 for U.S. Appl. No. 11/413,130.
Reply to Office Action mailed Dec. 7, 2006 for U.S. Appl. No. 11/413,130.
Office Action mailed Jul. 17, 2007 for U.S. Appl. No. 11/413,130.
Reply to Office Action mailed Jan. 16, 2008 for U.S. Appl. No. 11/413,130.
Office Action mailed Feb. 27, 2006 for U.S. Appl. No. 10/870,342.
Office Action mailed Mar. 23, 2007 for U.S. Appl. No. 10/870,342.
Reply to Office Action mailed Sep. 24, 2007 for U.S. Appl. No. 10/870,342.
Notice of Allowance mailed Nov. 9, 2007 for U.S. Appl. No. 10/870,342.
Reply to Office Action mailed Jan. 29, 2008 for U.S. Appl. No. 10/870,342.
Baker C. Hunter
Kim Yunsoo
President and Fellows of Harvard College
Wolf Greenfield & Sacks P.C.
LandOfFree
Methods, products and treatments for diabetes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods, products and treatments for diabetes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods, products and treatments for diabetes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2670337